Redeye reiterates its positive stance on Vicore and Base case of SEK 48 per share following today’s announcement of last-patient-in for the ATTRACT-trial. The trial includes 106 hospitalized Covid-19 patients – slightly more than planned (solely positive from a power POV). In our view, the objective endpoints in the trial enable a clear ‘stop or go’ decision for Vicore regarding the future clinical development of VP01 for Covid-19. Vicore expects to deliver data from the trial before the year-end. Although we regard the Covid-19 indication as a bonus in our investment case, encouraging data would create tremendous value for Vicore.